Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

被引：0
|
作者：
Heisen, M.
Treur, M. J.
van der Hel, W. S.
Groot, M. T.
Verheggen, B. G.
机构：
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Novartis Pharma BV, Arnhem, Netherlands
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [21] Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
    Kalincik, Tomas
    Brown, J. William L.
    Robertson, Neil
    Willis, Mark
    Scolding, Neil
    Rice, Claire M.
    Wilkins, Alastair
    Pearson, Owen
    Ziemssen, Tjalf
    Hutchinson, Michael
    McGuigan, Christopher
    Jokubaitis, Vilija
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva
    Trojano, Maria
    Izquierdo, Guillermo
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Sola, Patrizia
    Hupperts, Raymond
    Lechner-Scott, Jeannette
    Terzi, Murat
    Van Pesch, Vincent
    Rozsa, Csilla
    Grand'Maison, Francois
    Boz, Cavit
    Granella, Franco
    Slee, Mark
    Spitaleri, Daniele
    Olascoaga, Javier
    Bergamaschi, Roberto
    Verheul, Freek
    Vucic, Steve
    McCombe, Pamela
    Hodgkinson, Suzanne
    Sanchez-Menoyo, Jose Luis
    Ampapa, Radek
    Simo, Magdolna
    Csepany, Tunde
    Ramo, Cristina
    Cristiano, Edgardo
    Barnett, Michael
    Butzkueven, Helmut
    Coles, Alasdair
    LANCET NEUROLOGY, 2017, 16 (04): : 271 - 281
  • [22] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [23] COST MINIMIZATION ANALYSIS OF FINGOLIMOD COMPARED TO NATALIZUMAB IN PATIENTS WITH RELAPSE REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS
    Verheggen, B.
    Treur, M.
    Groot, M.
    VALUE IN HEALTH, 2011, 14 (07) : A323 - A323
  • [24] ECONOMIC EVALUATION OF NATALIZUMAB VERSUS FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SWEDEN
    Alexopoulos, S. T.
    Deniz, B.
    Walker, A. R.
    Arnold, R.
    Bates, D.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [25] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [26] Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis in real world clinical practice
    Totaro, R.
    Costantino, G.
    Bellantonio, P.
    Danni, M.
    Di Carmine, C.
    Fantozzi, R.
    Cerqua, R.
    Fuiani, A.
    Mundi, C.
    Ruggieri, S.
    Marini, C.
    Provinciali, L.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 267 - 267
  • [27] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [28] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
  • [29] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [30] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
    Derfuss, T.
    Bergvall, N. K.
    Sfikas, N.
    Tomic, D. L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
12345